How much does Alimera Sciences Limited make?

Alimera Sciences Limited reported revenue of £18.6m and a loss of £15.1m in the year to 31 Dec 2024, according to its accounts filed at Companies House.

How many employees does Alimera Sciences Limited have?

Alimera Sciences Limited reported an average of 29 employees in the year to 31 Dec 2024.

Is Alimera Sciences Limited profitable?

No — Alimera Sciences Limited reported a loss of £15.1m in the year to 31 Dec 2024.

Company No. 08018355 · Incorporated 3 Apr 2012

Alimera Sciences Limited

Registered name: ALIMERA SCIENCES LIMITED

Part of Ani Pharmaceuticals, Inc. group

Alimera Sciences Limited made £18.6m revenue and a £15.1m loss in the year to 31 Dec 2024.

Alimera Sciences Limited’s revenue grew 40% to £18.6m in the year to 31 Dec 2024, with a loss of £15.1m and 29 employees. The company is classified under “other business support service activities” and is based in Hook; we hold 2 years of its filed accounts.

Full P&L filedSection N · Administrative and support servicesSIC 82990Other business support service activities n.e.c.

Status: Active
Location: Hook, South East
Age: 14 yrs · since 2012
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2024

Key figures

Doing more with less

Revenue

£18.6m

Growth ▲40.2%

Profit

−£15.1m

Growth —

Profit margin

−81.3%

Gross 93%

Employees

Change ▼3.3%

Profit / employee

−£522k

Revenue/employee £642k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

2 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2023	31 Dec 2024
Disclosure	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£13.3m	£18.6m
Cost of sales	£933k	£1.3m
Gross profit	£12.3m	£17.3m
Operating profit	−£5.4m	−£9.9m
Profit before tax	−£10.3m	−£15.2m
Profit after tax	−£10.3m	−£15.1m
Profit (best available)	−£10.3m	−£15.1m
Employees (average)	30	29
Ratios
Profit margin	−77.4%	−81.3%
Gross margin	93%	93%
Revenue per employee	£442k	£642k
Profit per employee	−£342k	−£522k
Growth (year on year)
Revenue growth	—	▲40.2%
Headcount growth	—	▼3.3%
Balance sheet — indirect signals, not revenue
Cash at bank	£942k	£1.2m
Net assets	−£20.6m	−£34.7m
Fixed assets	£42.8m	£36.7m
Current assets	£10.9m	£17.6m
Debtors	£781k	£997k
Deferred income	£521k	£842k
Source	FullAccounts · bulk data Mar 2026	FullAccounts · bulk data Mar 2026

Derived from the latest filing

How the business works

Profit margin: −81.3%; Profit ÷ revenue.
Gross margin: 93%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £642k; Revenue ÷ average employees.
Profit per employee: −£522k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 197.2%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 4.5%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 5.4%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now −£34.7m
Cash at bank: ▲26%; Now £1.2m
Headcount: ▼3%; Now 29
Deferred income: ▲62%; Now £842k
Fixed assets: ▼14%; Now £36.7m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Ani Pharmaceuticals, Inc. (registered outside the UK register)ultimate parent75–100%
Alimera Sciences Limitedthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£15.1m), from the Companies House accounts bulk data published Mar 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.